Physician

Radha Kishan Adusumilli

According to 2025 Medicare claims, Radha Adusumilli (NPI: 1417441957) practices internal medicine in the Eagle Pass, TX market, with the plurality of this provider's patient population coming from Maverick, TX. This provider's primary affiliated billing organization is RENAL ASSOCIATES, P.A. (NPI: 1851368112; TIN: 742083988) and primary practice location at 78852-5893. Adusumilli is affiliated with the Caravan Health ACO 43 LLC (ACO ID: A4974), participating under the MSSP model.

Adusumilli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 268 traditional Medicare patients, billed 3,473 HCPCS/CPT codes, and received $113,650 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,755 prescription claims across 341 beneficiaries totaling $554,135 in drug costs, led by Jardiance (Empagliflozin). DME data shows 149 claims. Open Payments data shows 1 records totaling $13. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,952 to $554,135. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	115	573	$29,434
2024	268	3,473	$113,650

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	32	100	$3,952
2020	43	99	$2,951
2021	21	57	$3,429
2022	15	54	$5,694
2023	61	167	$57,682
2024	341	1,755	$554,135

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	149	$2,519

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	47	52	$130
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	83	317	$59
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	98	230	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	91	233	$12
36415	Insertion of needle into vein for collection of blood sample	119	431	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	134	9,685	$191,811
Farxiga	Dapagliflozin Propanediol	84	4,980	$94,762
Lokelma	Sodium Zirconium Cyclosilicate	61	2,123	$56,845
Ozempic	Semaglutide	21	1,050	$32,333
Januvia	Sitagliptin Phosphate	18	1,380	$25,800

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	39	$832
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	52	$677
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	30	$521
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	28	$489

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$13	Ardelyx, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Radha Kishan Adusumilli?

Tedicare shows public-source Medicare data for Radha Kishan Adusumilli (NPI 1417441957), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Radha Kishan Adusumilli have ACO affiliation data?

Radha Kishan Adusumilli is shown with ACO affiliation data for Caravan Health ACO 43 LLC (MSSP, ACO ID A4974).

What billing organization is linked to Radha Kishan Adusumilli?

Radha Kishan Adusumilli is linked to RENAL ASSOCIATES, P.A. (billing NPI 1851368112) in the available physician profile data.

Does Radha Kishan Adusumilli have Open Payments data?

Radha Kishan Adusumilli has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.